NYSE: MET

MetLife (MET) Stock Analysis & Forecast

MetLife, Inc. Finance sector, multi-line insurance industry. Market cap $62.44B.

$97.04−0.31 (−0.3%)

Close on Sep 18, 2026. Page updated Sep 19, 9:19 pm ET.

Gekko Brief

AI summary

MetLife trades at $97.04, down 0.3% on the day, sitting above both its 50-day average of $95.85 and its 200-day average of $82.92. The stock has gained 2% over one month, 13.4% over three months, and 41.4% over six months, and it trades within reach of its 52-week high of $100.93. The GekkoIndex reads 58.8, placing MetLife in the Neutral zone, and the price sits 2.5% below Gekko Fair Value of $99.53.

Recent activity centers on an analyst rating and a wave of ownership filings. Wall Street Zen cut its rating on MetLife from Buy to Hold, this coming after the company reported double-digit revenue growth, an earnings beat, and a new $3 billion share buyback program. Separately, several Rule 144 filings show MetLife-affiliated accounts, including a 401(k) plan, lining up small share sales through Cantor Fitzgerald, while Nykredit A/S disclosed a new stake of over 2.11 million shares valued at approximately $178.6 million and Bank of America Corp DE acquired over 5.38 million shares valued at approximately $455.4 million.

The next earnings date falls on 4 November 2026, 45 days out and beyond a typical 20-trading-day hold; the prior quarter's report on 5 August 2026 produced a 4% reaction on EPS of $2.43 against an estimate of $2.30, with four beats over the last eight quarters and an average absolute reaction of 2.6%. Seasonally, the next 20 trading days have averaged a 2.6% return over 5 years, rising in 2 of those years. Analyst consensus across 12 firms shows 10 buy and 2 hold ratings, with a consensus target of $105.06.

Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.

Price vs fair value

Close $97.04200-day averageGekko Fair Value $99.53

Key stats

Market cap
$62.44B
P/E ratio
18.6
Forward P/E
10.7
EPS, TTM
$5.23
Revenue, TTM
$79.40B
Profit margin
4.6%
Dividend yield
2.36%
Beta
0.76
Volume
7.31M avg 3.05M
1-year return
+23.3%
Typical daily move
±1.9%
Typical 20-day move
±4.5%
50-day average
$95.85
200-day average
$82.92
Next earnings
Nov 4
Shares outstanding
635.5M
52-week range
$67.33$100.93

MetLife swing-trade checklist

MetLife scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive3 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $97.04 is above the 50-day ($95.85) and 200-day ($82.92) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    58.8, Neutral

    Reading 58.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    2.5% below

    Price is within 5% of Gekko Fair Value (2.5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 45 days

    Next report Nov 4, 2026, 45 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitymixed

    +2.6% on average

    From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

MetLife stock chart and price history

MetLife closed at $97.04 on Sep 18, 2026, +23.3% over the past year, inside a 52-week range of $67.33 to $100.93.

Close50-day average200-day averageVolume

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+2.0%
3 months
+13.4%
6 months
+41.4%
1 year
+23.3%
The full MET chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open MET in Gekko

Follow MetLife through every session

Put MET on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track MET in GekkoFree for 7 days. No credit card required.

About MetLife

MetLife sells insurance and related financial products to individuals and businesses, covering areas like life coverage, dental, disability, pet, vision and accident protection, plus prepaid legal plans. It is widely known for the sheer range of coverage types it packages together for both personal policyholders and workplace benefit programs.

Operationally, the company is split into five regional and business segments, covering the United States, Asia, Latin America, Europe/Middle East/Africa, and a separate unit for older policy blocks called MetLife Holdings. It works with employers on benefits administration, structures pension risk transfer deals, sells institutional annuities and settlement products, and builds investment offerings for capital markets clients. Customers can also access various annuity styles such as fixed, indexed and variable contracts, along with whole, term, universal and group life policies, plus reinsurance for longevity risk, credit-linked insurance, and coverage aimed at long-term care needs and executive benefit funding.

MetLife traces back to 1863 and runs its headquarters out of New York City. The stock trades on the NYSE under the ticker MET.

Listed
NYSE
Sector
Finance
Industry
Multi-line insurance
Website
metlife.com

MetLife GekkoIndex: the smart money zone

MetLife’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.8, in the Neutral zone, up 1.5 points over five sessions.

010058.8Neutral

Up 1.5 points over five sessions.

Reading for Sep 18, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying10+3.5%+4.4%+10.4%+16.6%
Accumulation190+0.7%+1.5%+2.4%+3.9%
Neutral (current zone)423+0.2%+0.1%+0.6%+1.8%
Distribution38−0.7%+0.3%+0.3%+6.8%
Selling1Too few readings yet

Average MET share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the MET price, zone by zone.Track MET in Gekko

Is MetLife stock overvalued? Gekko Fair Value

MetLife trades 2.5% below Gekko Fair Value of $99.53, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what MetLife shares are worth, recalculated every trading day.

$99.53

Gekko Fair Value, Sep 19, 2026

2.5% below fair value · About fair value

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open MET in Gekko

MetLife insider and Congress trading

No open-market insider purchases were filed for MetLife, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for MET in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every MET insider filing, plotted on the chart in Gekko.Open MET in Gekko

Congress trades last 90 days

No trades in MET were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for MET, plotted on the chart in Gekko.Open MET in Gekko

Buybacks

MetLife has been buying back its own shares.

Latest authorization
$3.00B, Aug 5, 2026
Bought back, quarter ended Jun 30, 2026
$722.0M
As a share of market cap
1.16%
Trailing four quarters
$2.44B

From company filings.

Hedge funds and billionaires quarter ended Jun 30

1of the funds Gekko tracks holds MET.

0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko

MetLife earnings: next date and track record

MetLife reports on Nov 4, 2026 (45 days away), and beat the EPS estimate in 4 of its last 8 reports.

4 of 8reports beat the EPS estimate
±2.6%average move across the report
1 of 8reports followed by a gain

Share-price move across each report

−5.3%Oct ’24−1.1%Feb ’25−0.9%Apr ’25−1.4%Aug ’25−4.4%Nov ’25−2.1%Feb ’26−1.4%May ’26+4.0%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
MetLife reported Q2 2026 adjusted earnings of ~$1.6B ($2.43/share), up 15% YoY, with EPS growing 20%. Adjusted ROE hit 17%, at the top of the 15-17% target range. Group Benefits earnings rose 25% YoY with Group Life mortality ratio of 79%. Adjusted premiums/fees grew 5% YoY, sales rose 7%, and the direct expense ratio held at 12.1% despite PineBridge integration. All business segments showed YoY earnings growth.
Guidance
Management reaffirmed full-year direct expense ratio target of 12.1% and annual adjusted ROE target of 15-17%. AI investments and PineBridge integration are expected to support durable long-term growth and productivity gains while maintaining return standards.
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$2.43
est $2.30
+5.7%$19.08B
est $19.67B
−3.0%+4.0%
May 6, 2026$2.42
est $2.27
+6.6%$19.07B
est $19.49B
−2.1%−1.4%
Feb 4, 2026$2.58
est $2.34
+10.3%$23.81B
est $27.22B
−12.5%−2.1%
Nov 5, 2025$2.34
est $2.31
+1.3%$16.88B
est $18.64B
−9.4%−4.4%
Aug 6, 2025$2.02
est $2.15
−6.0%$17.34B
est $18.53B
−6.4%−1.4%
Apr 30, 2025$1.96
est $2.00
−2.0%$18.28B
est $18.37B
−0.5%−0.9%
Feb 5, 2025$2.09
est $2.09
0.0%$18.38B
est $19.50B
−5.8%−1.1%
Oct 30, 2024$1.95
est $2.18
−10.6%$18.44B
est $18.66B
−1.2%−5.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

MetLife stock forecast and analyst price targets

Analysts’ average 12-month price target for MetLife is $105.06, +8.3% from the last close, from 12 firms rating the stock in the last 90 days.

$105.06consensus 12-month target, +8.3% from the last close
Low $90High $119
Buy10
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 12 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Aug 24Morgan StanleyBuy, reiterated$111+14.4%
Aug 19Wells FargoBuy, maintained$109+12.3%
Aug 18Wells FargoBuy, maintained$109+12.3%
Aug 11Mizuho SecuritiesBuy, maintained$112+15.4%
Aug 11J.P. MorganBuy, maintained$108+11.3%
+0.6%average 20-day move after past Neutral readings
+2.6%average move over the next 20 trading days in the last 5 years
±1.9%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

MetLife seasonality: the next 20 trading days

Over the next 20 trading days from Sep 19, MetLife averaged +2.6% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

+9.9%20210.0%2022−3.6%2023+5.7%2024−0.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.2%3 of 5
Next 10 trading days−0.5%3 of 5
Next 15 trading days+1.3%3 of 5
Next 20 trading days+2.6%2 of 5
Next 30 trading days+3.0%4 of 5

For scale, MET’s typical 20-trading-day move in either direction is about 4.5%.

MetLife market cap and key statistics

MetLife’s market cap is $62.44B, with a P/E ratio of 18.6 and revenue of $79.40B over the last twelve months.

Valuation

Market cap
$62.44B
P/E ratio
18.6
Forward P/E
10.7
EPS, TTM
$5.23
Gekko Fair Value
$99.53

Trading

Volume
7.31M
Avg volume, 20 days
3.05M
52-week high
$100.93
52-week low
$67.33
Shares outstanding
635.5M

Financials

Revenue, TTM
$79.40B
Profit margin
4.6%
Return on equity
13.1%
Quarterly earnings growth, YoY
+5.8%

Risk and income

Beta
0.76
Typical daily move
±1.9%
Typical 20-day move
±4.5%
Dividend yield
2.36%

MetLife stock news this week

Coverage of MetLife this week reads positive: 6 positive, 6 neutral and 1 negative headlines.

News sentiment positive

MetLife peers

MetLife’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
PGRProgressive−0.3%Accumulation3.9% below
MFCManulife Financial+0.7%Neutral10.8% above
ALLAllstate−0.6%Accumulation5.6% below
AFLAFLAC+0.7%Accumulation2.9% below
SLFSun Life Financial+1.0%Neutral9.1% above
AIGAIG+0.2%Accumulation8.0% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

MetLife stock FAQ

What is MetLife’s market cap?

MetLife’s market cap is $62.44B at the Sep 18, 2026 close of $97.04, with 635.5M shares outstanding. The shares trade on a P/E ratio of 18.6.

What is the MetLife stock forecast?

The consensus analyst 12-month price target for MetLife is $105.06, +8.3% from the last close. Of the 12 firms that rated the stock in the last 90 days, 10 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is MetLife stock overvalued or undervalued?

On Gekko’s estimate MetLife is about fair value: the Sep 18, 2026 close of $97.04 is 2.5% below Gekko Fair Value of $99.53. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does MetLife report earnings next?

MetLife is expected to report on Nov 4, 2026 (45 days away). Analysts expect earnings of $2.55 per share on revenue of $20.10B. MetLife beat the earnings estimate in 4 of its last 8 reports, moving 2.6% on average across the report.

What is MetLife’s 52-week high and low?

MetLife’s 52-week high is $100.93 and its 52-week low is $67.33; it closed at $97.04 on Sep 18, 2026, +23.3% over the past year.

Is MetLife stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.

How this page works

Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See MetLife the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,349 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.